abstract |
Novel pyrazolobenzodiazepines having formula (I) and the pharmaceutically acceptable salts thereof, wherein R1, R2, R3 and R4 are as defined herein inhibit cyclin-dependent kinases (CDKs), in particular CDK2, are anti- proliferative agents useful in the treatment or control of cell proliferative disorders, in particular breast, colon, lung and prostate tumors. |